<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418728</url>
  </required_header>
  <id_info>
    <org_study_id>CME2014 /450</org_study_id>
    <nct_id>NCT02418728</nct_id>
  </id_info>
  <brief_title>The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise</brief_title>
  <acronym>BALO</acronym>
  <official_title>The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to
      co-morbidities and as a result, obesity significantly shortens life expectancy and lowers
      quality of life. To prevent this, participation in exercise or training programs is
      absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose
      tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine
      regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large
      variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to
      a decreased lipolytic effect of these hormones (as was shown for catecholamines in the
      subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial
      natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with
      obesity, which show an increased plasma expression of atrial natriuretic peptide.

      The aim of the present study is to observe the contribution of atrial natriuretic peptide in
      the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of
      extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ
      at rest and during endurance exercise under local beta- and alpha-blockade.

      Eventually, the knowledge gained from this research will contribute to the optimization of
      exercise programs for people with obesity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subcutaneous adipose tissue microdialysis</measure>
    <time_frame>week 1</time_frame>
    <description>abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial natriuretic peptide (ANP) Response</measure>
    <time_frame>week 1</time_frame>
    <description>measurement systemic ANP response (venous blood sampling)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central insulin sensitivity</measure>
    <time_frame>screening</time_frame>
    <description>Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Day 1</time_frame>
    <description>heart function by means of standard echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen uptake (ml/O2/kg/min)</measure>
    <time_frame>Day 1</time_frame>
    <description>measured using indirect calorimetry and an incremental bicycle protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>screening</time_frame>
    <description>body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal subcutaneous adipose tissue biopsy</measure>
    <time_frame>week 1</time_frame>
    <description>biochemical, proteomics and morphological analyses</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>persons with obesity</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>lean persons</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>subcutaneous adipose tissue microdialysis under local beta/alpha blockade</intervention_name>
    <description>adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis</description>
    <arm_group_label>persons with obesity</arm_group_label>
    <arm_group_label>lean persons</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        subjects with obesity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese group: BMI &gt; 30 kg/m², sedentary (no regular physical activity last 6 months),
             insulin sensitive or insulin resistant

          -  Lean controls: BMI &gt; 18.5 kg/m² and &lt; 25 kg/m², regular physical activity, insulin
             sensitive

        Exclusion Criteria:

          -  Regular glucose lowering medication or beta blockade medication

          -  Presence of chronical diseases

          -  Orthopedic or neurological problems
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Blaak, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Verboven, drs</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hasselt University</name>
      <address>
        <city>Diepenbeek</city>
        <zip>3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Dominique Hansen</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>adipose tissue lipolysis</keyword>
  <keyword>lipolysis</keyword>
  <keyword>microdialysis</keyword>
  <keyword>atrial natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

